Results 111 to 120 of about 61,341 (287)

Use of glucagon‐like peptide‐1 receptor agonists in patients with left ventricular assist devices

ESC Heart Failure, EarlyView.
Key question: does GLP1‐RA therapy improve heart transplantation rates and clinical outcomes in patients with LVADs? Key findings: in this propensity score‐matched cohort study of 1068 LVAD recipients, GLP1‐RA use was associated with higher heart transplantation rates (18.9% vs.
Ramzi Ibrahim, Hoang Nhat, Mahmoud Abdelnabi, Beani Forst, Mohamed Allam, Xuan Ci Mee, Ghee Kheng Lim, George Bcharah, Timothy Barry, Juan Farina, Chadi Ayoub, Reza Arsanjani, Kwan Lee   +12 more
wiley   +1 more source

Spironolactone in cardiovascular disease: an expanding universe? [version 1; referees: 2 approved]

F1000Research, 2017
Spironolactone has been marketed for over half a century as a ‘potassium-sparing diuretic’, used primarily in patients with ascites. With the realization that primary aldosteronism is the most common (5-13%) form of secondary hypertension, it has become ...
John W. Funder
doaj   +1 more source

Safety of low-dose spironolactone administration in chronic haemodialysis patients [PDF]

, 2017
Background. Prevention of cardiovascular diseases is essential in chronic haemodialysis patients. Recently, low-dose spironolactone has been shown to decrease cardiovascular mortality in patients with severe heart failure.
Fumeaux, Zina, Mach, Francois, Martin, Pierre-Yves, Perneger, Thomas, Rossier, Michel, Saudan, Patrick, Schnetzler, Bruno, Stoermann, Catherine   +7 more
core  

Alterations in vascular function in primary aldosteronism - a cardiovascular magnetic resonance imaging study [PDF]

, 2014
Introduction: Excess aldosterone is associated with increased cardiovascular risk. Aldosterone has a permissive effect on vascular fibrosis. Cardiovascular magnetic resonance imaging (CMR) allows study of vascular function by measuring aortic ...
A McCurley, A Rudolph, A Tomaschitz, B Fink, B Strauch, B Strauch, C Catena, C Delles, C Delles, CB Stehr, D Rizzoni, DA Calhoun, E M Freel, E P McQuarrie, EM Freel, G Bernini, GE Callera, GF Mitchell, GP Rossi, JM Connell, JW Funder, K Gaddam, L U Zimmerli, LU Zimmerli, MJ van Trijp, MR Robinson, NC Edwards, OJ Rider, OJ Rider, P B Mark, P Milliez, P Rerkpattanapipat, PB Mark, R Holaj, R Rocha, RB Stacey, S Boyle, S Laurent, T Indra, WJ Rogers, YH Lin   +40 more
core   +1 more source

Epidemiology, pathophysiology, diagnosis and management of atrial functional mitral regurgitation: An expert opinion paper

ESC Heart Failure, EarlyView.
The graphical abstract summarizes the key features of AFMR in terms of epidemiology, pathophysiology, diagnosis, medical therapy and rhythm control, surgical and transcatheter interventions, and future directions. Created in BioRender (https://BioRender.com/3zj03ko).
Matteo Pagnesi, Mauro Riccardi, Francesco Maisano, Julia Grapsa, Vassilis Barberis, Magdy Abdelhamid, Elena‐Laura Antohi, Henrike Arfsten, Nicole Karam, Denisa Muraru, Karl‐Philipp Rommel, Anna Sannino, Wilfried Mullens, Marianna Adamo, Marco Metra   +14 more
wiley   +1 more source

Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study

ESC Heart Failure, EarlyView.
Abstract Aims Inflammation is postulated to be a key pathogenic mechanism in heart failure with preserved ejection fraction (HFpEF). Soluble urokinase plasminogen activator receptor (suPAR), a regulator of innate immune activity, is associated with incident heart failure; however, its role in HFpEF remains unclear.
Christina G. Hutten, Annika Tekumulla, Anis Ismail, Alexi Vasbinder, Theresa Farhat, Pennelope Kunkle, Sascha N. Goonewardena, Ahmed Abdel‐Latif, Bertram Pitt, Salim S. Hayek   +9 more
wiley   +1 more source

Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

ESC Heart Failure, EarlyView.
Abstract Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart ...
Kristian Hellenkamp, Sophia Kaebe, Miroslava Valentova, Stephan von Haehling, Fani Delistefani, Katja Gollisch, Dirk Raddatz, Ann‐Kathrin Schäfer, Michael J. Koziolek, Manuel Wallbach   +9 more
wiley   +1 more source

Impact of early intensive GDMT on LVEF recovery and ICD decision making in de novo HFrEF

ESC Heart Failure, EarlyView.
Abstract Aims Implantable cardioverter‐defibrillator (ICD) implantation is recommended in patients with heart failure with reduced ejection fraction (HFrEF) and left ventricular ejection fraction (LVEF) ≤ 35% after 3 months of optimized medical therapy (OMT).
Diogo Rosa Ferreira, Daniel Inácio Cazeiro, Joana Brito, Rafael Santos, Joana Rigueira, Doroteia Silva, Nuno Lousada, Fausto Pinto, Dulce Brito, João Agostinho   +9 more
wiley   +1 more source

Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study

ESC Heart Failure, EarlyView.
In this prospective registry of 1401 heart failure outpatients, patients with eGFR <60 mL/min/1.73m2 had lower achievement of target RASi and MRA doses, with the lowest absolute use in patients with eGFR <30. Beta blockers were consistently prescribed across all heart failure phenotypes and kidney function.
Chen Hsiang Ma, Arthur Qi, Luke Gagnon, Kaiming Wang, Chandu Sadasivan, Anukul Ghimire, Matthew Cooper, Somkanya Tungsanga, Bonaventure Oguaju, Ben Vandermeer, Finlay A. McAlister, Aminu K. Bello, Gavin Y. Oudit   +12 more
wiley   +1 more source

Assessment and Management of Hypertension among Patients on Peritoneal Dialysis [PDF]

, 2019
Approximately 7%-10% of patients with ESKD worldwide undergo peritoneal dialysis (PD) as kidney replacement therapy. The continuous nature of this dialytic modality and the absence of acute shifts in pressure and volume parameters is an important ...
Agarwal, Rajiv, Georgianos, Panagiotis I., Liakopoulos, Vassilios, Vaios, Vasilios   +3 more
core   +1 more source